Physician profile
Sanjeev Dewan
NPI 1295702066
$3,131.07
in general payments reported to CMS, 2019-2025
30 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $156 · 2021: $376 · 2022: $232 · 2023: $395 · 2024: $719 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807 · Education: $99.99 · Entertainment: $29.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.13 |
| Education | $99.99 |
| Entertainment | $29.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $776.55 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Ocular Therapeutix, INC. | $297.93 | 2019-2025 | Dextenza |
| Ivantis, INC | $209.12 | 2019-2021 | |
| Sight Sciences, INC. | $202.95 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $195.51 | 2021-2023 | Tepezza |
| Harrow Eye, LLC | $190.23 | 2023-2025 | Iheezo |
| Mallinckrodt Hospital Products INC. | $165.82 | 2021-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $114.64 | 2019-2022 | |
| Abbvie INC. | $110.43 | 2022-2024 | Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.97 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $86.21 | 2019-2022 | |
| Oyster Point Pharma, INC. | $84.83 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $80.71 | 2024-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite, Idosetr |
| Allergan, INC. | $79.94 | 2020-2022 | |
| Rayner Intraocular Lenses Limited | $76.03 | 2024-2025 | Omidria, Rayone Emv, Rayone Aspheric |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $64.19 | 2019-2025 | |
| Thea Pharma INC. | $37.62 | 2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $32.70 | 2020-2021 | |
| Optos, INC. | $29.21 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $24.05 | 2024 | Xdemvy |
| Alexion Pharmaceuticals, INC. | $23.95 | 2025 | Ultomiris |
| Dompe US, INC. | $22.54 | 2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $21.68 | 2025 | Iluvien |
| Bausch & Lomb Americas INC. | $19.50 | 2025 | Scoutpro Osmolarity System |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Amgen INC. | $16.64 | 2025 | Tepezza |
| Lkc Technologies, INC. | $15.74 | 2025 | |
| Alimera Sciences, INC. | $13.17 | 2020 | |
| Omeros Corporation | $12.27 | 2019 | |
| New World Medical,INC. | $11.70 | 2023-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Dewan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.